

## Accepted Manuscript

Chitosan-hydroxypropyl methylcellulose tioconazole films: A promising alternative dosage form for the treatment of vaginal candidiasis

Natalia L. Calvo, Laura A. Svetaz, Vera A. Alvarez, Ariel D. Quiroga, María C. Lamas, Darío Leonardi

PII: S0378-5173(18)30917-7  
DOI: <https://doi.org/10.1016/j.ijpharm.2018.12.011>  
Reference: IJP 17980

To appear in: *International Journal of Pharmaceutics*

Received Date: 17 September 2018  
Revised Date: 30 November 2018  
Accepted Date: 4 December 2018

Please cite this article as: N.L. Calvo, L.A. Svetaz, V.A. Alvarez, A.D. Quiroga, M.C. Lamas, D. Leonardi, Chitosan-hydroxypropyl methylcellulose tioconazole films: A promising alternative dosage form for the treatment of vaginal candidiasis, *International Journal of Pharmaceutics* (2018), doi: <https://doi.org/10.1016/j.ijpharm.2018.12.011>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



1 **Chitosan-hydroxypropyl methylcellulose tioconazole films: A promising alternative**  
2 **dosage form for the treatment of vaginal candidiasis**

3  
4  
5 Natalia L. Calvo<sup>a,b</sup>, Laura A. Svetaz<sup>c</sup>, Vera A. Alvarez<sup>d</sup>, Ariel D. Quiroga<sup>e,f</sup>, María  
6 C. Lamas <sup>a,g,\*</sup>, Darío Leonardi <sup>a,g,\*</sup>

7  
8 <sup>a</sup>Instituto de Química Rosario (IQUIR, CONICET-UNR), Suipacha 531, Rosario  
9 (S2002LRK), Argentina.

10 <sup>b</sup>Área Análisis de Medicamentos, Facultad de Ciencias Bioquímicas y Farmacéuticas,  
11 Universidad Nacional de Rosario, Suipacha 531, Rosario (S2002LRK), Argentina.

12 <sup>c</sup>Área Farmacognosia, Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad  
13 Nacional de Rosario, Suipacha 531, Rosario (S2002LRK), Argentina.

14 <sup>d</sup>Grupo de Materiales Compuestos Termoplásticos (CoMP), Instituto de Investigaciones de  
15 Ciencia y Tecnología de Materiales (INTEMA, CONICET-UNMDP), Colón 10890, Mar del  
16 Plata (7600), Argentina.

17 <sup>e</sup>Instituto de Fisiología Experimental (IFISE, CONICET-UNR), Suipacha 531, Rosario  
18 (S2002LRK), Argentina.

19 <sup>f</sup>Área Morfología, Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad Nacional  
20 de Rosario, Suipacha 531, Rosario (S2002LRK), Argentina.

21 <sup>g</sup>Área Técnica Farmacéutica, Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad  
22 Nacional de Rosario, Suipacha 531, Rosario (S2002LRK), Argentina.

23  
24  
25  
26  
27  
28 Corresponding authors

29 Phone: 54-341-4804592. FAX: 54-341-4370477. Facultad de Ciencias Bioquímicas y  
30 Farmacéuticas, Universidad Nacional de Rosario, Suipacha 531, 24 (2000) Rosario,  
31 Argentina.

32 E-mail addresses: [leonardi@iquir-conicet.gov.ar](mailto:leonardi@iquir-conicet.gov.ar) (D. Leonardi), [mlamas@fbioyf.unr.edu.ar](mailto:mlamas@fbioyf.unr.edu.ar)  
33 (M. Lamas)

34 **Abstract**

35

36 Vaginal candidiasis is considered a frequent opportunistic mucosal infection and the second  
37 most common cause of vaginitis after bacterial vaginosis. In this work, different vaginal films  
38 based on chitosan, hydroxypropyl methylcellulose and blends of these polymers containing  
39 tioconazole, were developed and thoroughly characterized to improve the conventional  
40 therapeutics of vaginal candidiasis. Mechanical properties, swelling, adhesiveness,  
41 morphology, antifungal activity, hemocompatibility and cytotoxicity were evaluated. The  
42 drug solid state in the films was analyzed by thermal and X-ray diffraction analysis. Films  
43 showed homogeneous surfaces and presented similar mechanical properties and adhesiveness.  
44 Time-kill studies displayed that films were more active than both tioconazole pure drug and  
45 traditional tioconazole ovule against *Candida albicans*, which is probably related to the fact  
46 that tioconazole is in amorphous state inside the films. Although all formulations proved to be  
47 hemocompatible, films based only on chitosan exhibited a certain degree of cytotoxicity and  
48 therefore they should be avoided. The system based on chitosan-hydroxypropyl  
49 methylcellulose with 40% PEG 400 as plasticizer presented fast antimicrobial activity as well  
50 as the lowest swelling. Additionally, this formulation did not produce substantial hemolytic  
51 and cytotoxic effects, indicating that films based on chitosan-hydroxypropyl methylcellulose  
52 could be a promising alternative dosage form for the treatment of vaginal candidiasis.

53

54

55

56

57

58

59

60

61

62

63

64

64 Keywords: Vaginal candidiasis; Films; Mechanical properties; Antifungal activity;

65

Cytotoxicity

## 66 1. Introduction

67 Vaginal candidiasis is considered a frequent opportunistic mucosal infection in women,  
68 being the second most common cause of vaginitis after bacterial vaginosis (Egan and Lipsky,  
69 2000). The disease affects 70 - 75% women at least once in their lifetime and around 50% of  
70 patients experience a recurrence (Costa-de-Oliveira et al., 2008). Although different *Candida*  
71 species may produce this disease, *Candida albicans* is the most prevalent yeast causing this  
72 infection. Vaginal candidiasis is commonly treated using azole antifungals, such as  
73 fluconazole, miconazole, itraconazole, clotrimazole, econazole, ketoconazole and tioconazole  
74 (Bassi and Kaur, 2015). Tioconazole (TCZ, (1[2-(2-chloro-3-thienyl) methoxy-2-(2,4-  
75 dichloro-phenyl)ethyl]-H-imidazole) is an imidazole antifungal agent with a broad spectrum  
76 of activity against a variety of microorganisms (Carrillo-Muñoz et al., 2010). This drug has  
77 been shown to hold higher activity against *C. albicans* than clotrimazole, econazole,  
78 ketoconazole and miconazole (Lefler and Stevens, 1984). This could be due to the fact that  
79 TCZ possesses antifungal activity even when yeast cells are in the stationary phase, while  
80 common antifungal agents such as ketoconazole and miconazole display with antimicrobial  
81 activity only when yeasts are in the growth phase (Beggs, 1984).

82 The effectiveness of a treatment is not only determined by the antifungal compound  
83 type, but also by the development of an adequate dosage form, which is determinant in the  
84 biological activity of a therapeutic system. Particularly, pharmaceutical dosage forms for local  
85 vaginal delivery need to remain in the site of infection as long as possible and to be able to  
86 release the active compound according to the treatment. The use of conventional vaginal  
87 formulations such as creams, gels, pessaries, and foams is discouraged due to their poor  
88 retention in the vaginal tract by the tract's self-cleansing action (Alam et al., 2007). Other  
89 conventional formulations such as vaginal tablets and ovules show good retention abilities,  
90 but both are rigid and may produce discomfort. Alternative bioadhesive vaginal formulations

91 such as films are suitable forms to achieve effective drug release for extended periods of time  
92 (Cautela et al., 2018; Ghosal et al., 2014; Machado et al., 2016; Mishra et al., 2017;  
93 Srinivasan et al., 2016; Traore et al., 2018; Yoo et al., 2009). In addition, these films present  
94 more flexibility than tablets and ovules, which may improve patients' compliance.

95 Several biocompatible polymers such as chitosan (CH) and hydroxypropyl methyl  
96 cellulose (HPMC) have been employed to develop mucoadhesive films. CH, a cationic natural  
97 polymer widely used in pharmaceutical applications shows attractive biological properties  
98 including biocompatibility, biodegradability, non-toxicity, and physiological inertness  
99 (Krajewska, 2004). HPMC, a non ionic polymer, is a semi-synthetic cellulose derivative  
100 usually employed in the pharmaceutical industry, mainly as gelling agent and to control the  
101 release of pharmaceutical drugs (Kamel et al., 2008; Saha and Bhattacharya, 2010).

102 The aim of this work was to develop and thoroughly characterize novel TCZ film  
103 dosage forms in order to improve the therapeutics of vaginal candidiasis. TCZ films were  
104 compared with the TCZ ovule, which is the traditional dosage form selected to treat the  
105 infectious disease.

106

## 107 **2. Materials and Methods**

### 108 2.1. Chemicals

109 TCZ raw material of pharmaceutical grade (BP 2002) and PEG 400 were acquired in  
110 Saporiti (Buenos Aires, Argentina). During the experiments, the drug was kept in a desiccator.  
111 Double-distilled water was used for the preparation of aqueous solutions. TCZ vaginal ovule  
112 (“Honguil” from Raymos laboratories) containing 0.30 g TCZ and excipients [liquid vaseline  
113 (0.45 g) and solid vaseline (1.35 g)] was acquired in a local Drugstore (Rosario, Argentina).  
114 CH (230 KDa average molecular weight and 80.6% of N-deacetylation) was supplied by  
115 Aldrich Chemical Co. (Milwaukee, WI, USA). HPMC (MW 250 kDa, methoxyl content 19-

116 24%, hydroxypropyl content 7-12%) was purchased from Eigenman & Veronelli (Milan,  
117 Italy). All other chemicals were of analytical grade.

118

## 119 2.2. Methods

### 120 2.2.1. Film preparation

121 Films were prepared by solvent evaporation. CH solution (1% w/v) was obtained  
122 dispersing CH in 1% v/v lactic acid (v/v). TCZ was suspended in PEG 400 used as plasticizer  
123 and added to the CH solution. Aqueous solution of HPMC (1% w/v) was prepared and stirred  
124 overnight. Then, CH solution was dripped over HPMC solution at 40 °C to avoid precipitation  
125 and stirred at 200 rpm (Boecco stirrer, Germany) for 1 h. Finally, the solutions were cast on  
126 10 cm diameter Petri dishes and dried at 40 °C. Unloaded films were developed following the  
127 same procedure but without adding TCZ to the mixtures, B1 consisted of 0.25:0.75  
128 (CH:HPMC) ratio and B2 1:0 (CH:HPMC) ratio. Dried films were removed from the Petri  
129 dishes and conditioned in a chamber at 25 °C and 80% RH for 24 h.

130

131 **Table 1.** Composition of loaded films.

Film	CH 1% w/v	HPMC 1% w/v	PEG (% w/w)	TCZ (% w/w)
S1	0.25	0.75	5	15
S2	1	-	5	15
S3	0.25	0.75	40	15
S4	1	-	40	15

132

### 133 2.2.2. Film Characterization

#### 134 2.2.2.1. Thickness (TH) and folding endurance (FE)

135 For each system, six thickness measurements were made (around and in the center of

136 the films) with a digital micrometer (Schwyz, China). Folding endurance was determined by  
137 repeatedly folding the films at the same place until they broke or were folded 300 times  
138 (meeting the assay) (Avachat et al., 2013).

139

140 2.2.2.2. Mechanical properties: Load at break (LB) and Elongation at Break (EB)

141 The mechanical strength of the films was evaluated by using an Instron universal testing  
142 machine, EMIC 2350 (Instron, Norwood, MA, USA) with a 50 N load cell. Films for each  
143 mechanical test were conditioned (at 25 °C and 75% RH for 24 h) and cut into strips (7 mm  
144 wide and 60 mm long) to evaluate tensile properties. The initial grip distance was 30 mm and  
145 the crosshead speed was 5.0 mm/min. The parameters obtained from stress/strain curves were  
146 load at break (maximum force at breaking), and elongation (calculated as the percentile of the  
147 change in the length of film with respect to the original distance between the grips). For each  
148 mechanical probe, three replicate measurements were performed.

149

150 2.2.2.3. *In vitro* mucoadhesive strength (MS)

151 An Instron universal testing machine, EMIC 2350 (Instron, Norwood, MA, USA) with a  
152 50 N load cell was employed to analyze the mucoadhesive strength of each film. The force  
153 required to detach each formulation from a disc of porcine vaginal mucosa (obtained from  
154 “Paladini” slaughterhouse, V.G. Galvez, Argentina) was measured. A portion of each film  
155 (2.5 cm diameter) was added to the upper end of the cylindrical probe and gum discs  
156 (obtained by punch biopsy and hydrated with 0.5 mL artificial vaginal fluid for 2 min) were  
157 horizontally attached to the lower end of the cylindrical probe by using double-sided adhesive  
158 tape (Tejada et al., 2018b). Simulated vaginal fluid pH value 4.2 (composed by (g L<sup>-1</sup>): NaCl,  
159 3.51; KOH, 1.40; Ca(OH)<sub>2</sub>, 0.222; bovine serum albumin, 0.018; lactic acid, 2.00; acetic acid,

160 1.00; glycerol, 0.160; urea, 0.400 and glucose, 5.00) was prepared according to previous  
161 literature (Owen and Katz, 1999).

162 Each film remained in contact with the gum for 1 min and it was then moved upwards  
163 at a constant speed (1.0 mm/min). The test was carried out in triplicate. The force required to  
164 detach each film from the gum disc was determined from the resulting force/time plot.

165

#### 166 2.2.2.4. Swelling index (SI)

167 Swelling measurements were determined by immersing an accurately weighted portion  
168 of the films (around 50 mg) in 0.5 mL simulated vaginal fluid at 37 °C.

169 Films were carefully removed at predetermined time intervals (0, 5, 10, 15, 20, 30, 45,  
170 60, 90, 120, 150, 180, 210, and 240 min), and the excess adhering moisture was gently blotted  
171 off, and weighed. Then, 0.5 mL of simulated vaginal fluid was added again. The swelling  
172 index was calculated using the weights of dried ( $W_o$ ) and swollen ( $W_s$ ) films (Eq. (1)). The  
173 test was carried out in triplicate.

174

$$175 \quad SI: \quad \frac{W_s - W_o}{W_o} \quad (\text{Eq. 1})$$

177

178

#### 179 2.2.2.5. Fourier transformed infrared spectroscopy (FTIR)

180 Infrared (IR) spectra were acquired in a Shimadzu Prestige 21 spectrometer (Shimadzu  
181 Corp., Kyoto, Japan) over a wave number range of 4000-600  $\text{cm}^{-1}$ . ATR (attenuated total  
182 reflectance) experiments were carried out with a diamond-based ATR accessory (GladiATR,  
183 Pike Technologies, Madison, USA) fitted with a Pike temperature control unit. An average of  
184 20 scans was used at a 4  $\text{cm}^{-1}$  resolution between 4000 and 600  $\text{cm}^{-1}$  in all cases. The  
185 temperature (30 °C), the amount of sample, and the pressure exerted on the sample during the



186 measurement were standardized. Each system was scanned three times and the measurements  
187 averaged.

188

#### 189 2.2.2.6. Thermal analysis

190 Calorimetric determinations were performed in a Linseis PT1000 differential scanning  
191 calorimeter (DSC, Linseis Inc., New Jersey, USA), operating under a constant nitrogen flow  
192 (8 mL/min). Each sample, 2 mg (TCZ) or 5-6 mg (ovule and films), was placed in closed  
193 aluminum pans perforated with a pin-hole to equilibrate pressure from the potential expansion  
194 of evolved gases or residual solvents, and heated from 40 to 145 °C at 10 °C/min. An empty  
195 pan was used as a reference.

196 Thermogravimetric analysis (TGA) tests were carried out using a thermal analyzer  
197 (Model TGA Q500, Hüllhorst, Germany). Samples (around 8 mg) were heated at a constant  
198 rate of 10 °C/min from room temperature up to 600 °C under a nitrogen flow of 30 mL/min in  
199 order to avoid thermo oxidative reactions.

200

#### 201 2.2.2.7. X-ray diffraction analysis (XRD)

202 X-ray diffractograms were obtained with a PAN analytical X'Pert PRO diffractometer  
203 (Netherlands) equipped with a monochromatic  $\text{CuK}_\alpha$  radiation source ( $\lambda = 1.5406 \text{ \AA}$ )  
204 operating at a voltage of 40 kV and current 40 mA at a scanning rate of 0.02 ° per sec. The  
205 scanning region was in a  $2\theta$  range from 5 ° to 40 °.

206

#### 207 2.2.2.8. Scanning electron microscopy (SEM)

208 The morphology of films was investigated by scanning electron microscopy (SEM,  
209 AMR 1000, Leitz, Wetzlar, Germany). Samples were mounted on an aluminum support using  
210 conductive, double-sided adhesive tape, and coated with a fine gold layer for 15 min at 70–80

211 mTorr in order to make them conductive before obtaining the SEM micrographs. All samples  
212 were examined using an accelerating voltage of 20 kV and magnifications of 200x, 1000x and  
213 5000x (Priotti et al., 2017).

214

#### 215 2.2.2.9. Dissolution Studies

216 Dissolution studies were performed in 900 mL of distilled water (pH 4.3 mimic to the  
217 vaginal tract) at 37°C, using a USP XXIV Apparatus 2 (Paddle Apparatus) (Hanson Research,  
218 SR8 8-Flask Bath, Ontario, Canada) with paddles rotating at 50 rpm (Pharmacopoeia, 2017;  
219 Tejada et al., 2018b). TCZ raw material (135 mg) was dispersed in the dissolution medium.  
220 Films (containing 135 mg TCZ) were fixed to the central shaft using cyanoacrylate adhesive  
221 (Pharmacopoeia, 2017; Shaker et al., 2018; Tejada et al., 2017b). At different time intervals:  
222 0, 5, 15, 30, 45, 60, 90, 120, 180, 240, and 360 min, aliquot of 5 mL each were taken (without  
223 replacement) using a 0.45 µm filter. The amount of dissolved TCZ was determined by  
224 spectroscopic measures at 225 nm using an Agilent 8453 UV-DAD spectrophotometer  
225 (Agilent Technologies, Santa Clara, USA). Determinations were performed in a quartz cell  
226 (10 mm optical path length) against a blank of dissolution media. The assay was carried out in  
227 triplicate.

228

#### 229 2.2.2.10. Biological Activity of loaded and unloaded films

##### 230 2.2.2.10.1. Halo zone test over time

231 Halo zone test was performed following the guidelines of the disc diffusion method  
232 described in CLSI document M44-A2 [36]. *C. albicans* (ATCC 10231) was cultured in  
233 Sabouraud's dextrose agar 24 h before testing. Testing was carried out on agar plates (150  
234 mm diameter) containing Mueller-Hinton agar, supplemented with 2% glucose (2 g/100 mL)  
235 and 0.5 µm/mL methylene blue, at a depth of 4.0 mm. The inoculants were prepared by

236 suspending five distinct colonies in 5 mL of sterile distilled water and shaking on a vortex  
237 mixer for 15 s. The agar surface was inoculated by dipping sterile cotton swabs into a cell  
238 suspension adjusted to a turbidity of a 0.5 McFarland standard (approximately  $1 - 5 \times 10^6$   
239 CFU/mL) and by streaking the plate surface in three directions. The plate was allowed to dry  
240 for 20 min, then the TCZ powder (0.34 mg), used as control, was placed attached to a Scotch  
241 tape onto the agar surface. Additionally, ovule content (mass equivalent to 0.34 mg TCZ) was  
242 embedded in a paper disc and placed onto the agar surface. Each film, paper disc, and Scotch  
243 tape was moved to another area of the culture after 2, 4, 6, 8, 10, 24, 48, 72, and 96 h (4 days).  
244 After that, the plates were incubated in air at 28°C and read after 24 h. Halo diameters (in  
245 millimeters) for the zone of complete inhibition were determined using a caliper, and the  
246 mean value was recorded (Tejada et al., 2018a).

247

#### 248 2.2.2.10.2. Time-kill

249 *C. albicans* ATCC 10231 was cultured in Sabouraud dextrose agar (SDA) 24 h before  
250 testing. The inoculum was prepared by suspending five distinct colonies in sterile distilled  
251 water and shaking on a vortex mixer for 15 s. Cell suspension was adjusted to the turbidity of  
252 a 0.5 McFarland standard (approximately  $1 - 5 \times 10^6$  CFU/mL). TCZ (0.34 mg), ovule (2.38 mg  
253 equivalent to 0.34 mg TCZ) and films (disc with a diameter of 5 mm equivalent to 0.34 mg  
254 TCZ) were placed in 5 mL of inoculum. The suspensions were mixed for 20 s with a vortex  
255 mixer, and samples (0.05 mL) were taken at 0, 30, 60, 90, 120, 150, 180, 210, 240 and 360  
256 min, and serially diluted before spreading onto SDA. The plates were incubated for 24 h and  
257 the viable colonies were evaluated. The time-kill curves (Cantón et al., 2009) were  
258 constructed by plotting the CFU/mL surviving at each time point in the presence and absence  
259 of the formulations. Experiments were conducted in triplicate and the mean number of  
260 survivors was determined.

## 261 2.2.2.11. Cytotoxicity of loaded and unloaded films

## 262 2.2.2.11.1. Extraction assay from films

263 To achieve the extraction of the film components, discs (5 mm diameter) were placed  
264 in the sidewalls of a 12 well plate and Dulbecco's modified Eagle's medium (DMEM, 1200  
265  $\mu\text{L}$ ) was added to each well and incubated at 37 °C for 12-16 h. Then, the media were used for  
266 the analysis of cellular metabolic activity by MTT assay.

267

## 268 2.2.2.11.2. Cytotoxicity

269 Human HCC cell lines Huh7 were obtained from JCRB Cell Bank (Tokyo, Japan).

270 The top priority of this assay was to measure cell damage by the drugs. The use of different  
271 cell lines other than vaginal-derived cells was considered as a proper system since we did not  
272 mean to measure any hepatic effects; rather, we measured cytotoxicity of the drugs and their  
273 combinations with polymers. Allen et al. reported that cell lines tend to exhibit problems in  
274 stability and/or viability, and because of this, they do not always prove to be the ideal system.  
275 Thus, the use of cell lines able to overcome these limitations, such as those derived from other  
276 tissues, is recommended as a feasible alternative, especially regarding new potential  
277 applications in drug testing therapy (Allen et al., 2005). Cells were maintained in Dulbecco's  
278 modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum, 100 IU/mL  
279 penicillin, and 100  $\mu\text{g}/\text{mL}$  streptomycin at 37 °C in a humidified atmosphere of 95% O<sub>2</sub> and  
280 5% CO<sub>2</sub>. In all experiments, cells were treated after 24 h of attachment with 200  $\mu\text{L}$  extraction  
281 media. Control (untreated) cells were incubated without TCZ.

## 282 2.2.2.11.3. MTT assay

283 Cells were seeded in 96-well plates at a density of 3500 cells/well. After 24 h of  
284 attachment, cells were treated for 24 h with the different extraction media obtained in section

285 2.2.2.10.1. After treatment, 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium  
286 bromide (MTT; Sigma-Aldrich Corp.) was added into the culture medium to assess its  
287 metabolization, as previously described (Ferretti et al., 2016). Absorbance of the metabolite  
288 produced from viable cells was detected at 540 nm (reference filter 650 nm) in a DTX 880  
289 multimode detector (Beckman Coulter Inc., Fullerton, CA, USA). Results were expressed as  
290 percentage of absorbance in control cells.

291

#### 292 2.2.1.12. Statistical analysis and graphics software

293 Analysis of variance was used, and when the effect of the factors was significant, the  
294 Tukey multiple ranks honestly significant difference test was applied (Origin 8.5,  
295 OriginLabCo., Northampton, USA). Differences at  $p < 0.01$  were considered significant.

296

### 297 3. Results and discussion

#### 298 3.1. Mechanical properties


299 Loaded and unloaded films were uniform in texture. The thickness (Figure 1A) was  
300 found to range from  $0.197 \pm 0.064$  to  $0.297 \pm 0.033$  mm, which was significantly smaller than  
301 the ovule (25x10x10 mm). Therefore, the films could produce lesser discomfort after  
302 application than the ovule. It should be mentioned that the thickness of the films was even  
303 smaller than that obtained by Dobarra et al. They developed itraconazole bioadhesive vaginal  
304 films and considered as the optimal formulation a film with a thickness of 0.46 mm (Dobarra  
305 et al., 2009). Folding endurance was performed in order to evaluate film flexibility to produce  
306 a secure application. Prepared films were folded 300 times without breaking, meeting the  
307 folding endurance test (Avachat et al., 2013). The elongation value (Figure 1B) of film S4  
308 (based on CH and 40 % w/w PEG 400) was the highest ( $p < 0.01$ ). This fact could be  
309 explained by the combination of both high CH concentration and high percentage of

310 plasticizer. This result is in agreement with that previously obtained by Suyatma et al.  
311 (Suyatma et al., 2005), where the highest elongation for CH films was obtained when PEG  
312 400 at 40% was used as plasticizer. Also, when comparing formulations S3 and S4, it can be  
313 noted that a high HPMC ratio (0.75) produces a decrease in the elasticity values of the films.  
314 These results are in agreement with those obtained by Tejada et al., indicating a remarkable  
315 reduction in the elongation values of CH films when combined with HPMC at 50% w/w  
316 (Tejada et al., 2017a). It is worth mentioning that high concentrations of plasticizers  
317 combined with CH as a polymer former could increase the elongation value, producing a  
318 decrease in the tensile strength (Domjan et al., 2009); however, load at break values (Figure  
319 1C) ranged from 9 to 11 N with no significant differences among them ( $p > 0.01$ ). The  
320 characteristics of films, based on biopolymers depend on an equilibrium between the degree  
321 of interactions in the polymeric matrix (which may induce brittleness), and the addition of  
322 plasticizers for better workability. It has been reported that above a critical concentration, the  
323 plasticizer can exceed the compatibility limit with the biopolymer, and phase separation with  
324 plasticizer exclusion is usually observed (Vieira et al., 2011). In this work the combinations of  
325 CH, HPMC, and PEG 400 at the assayed concentrations produced neither brittleness nor  
326 phase separation.

327

328

329



330

331

332 **Figure 1.** A) Thickness, B) Elongation at break C) Load at break D) Mucoadhesive strength  
 333 E) Swelling index

334

335 3.2. Films swelling and adhesiveness

336 Figure 1E shows that films based only on CH (S2 and S4) swelled more than CH-  
 337 HPMC films (S1 and S3), this fact could be related with the pH value of the simulated  
 338 vaginal fluid (pH=4.2). At this pH value, CH is protonated (Dey et al., 2018; Wang et al.,  
 339 2006); thus, the more CH, the more charges, so there is more interaction with simulated  
 340 vaginal fluid and more fluid retention. The presence of HPMC in the formulated films did  
 341 not improve the swelling process due to the fact that high concentrations of HPMC could  
 342 decrease water permeability. Additionally, different results of the swelling process could  
 343 be due to the presence of the plastizicer. Conzatti et al. clearly described a CH  
 344 formulation film, employing high PEG 400 concentrations as a plastizicer, observing

345 PEG-PEG interactions instead of PEG-CH interactions (Conzatti et al., 2018).  
346 Consequently, a more organized, rigid structure was obtained, and thus the swelling could  
347 decrease. This phenomenon is observed in Figure 1E. Formulation S2 presented  
348 maximum swelling values, followed by formulation S4. The presence of high  
349 concentrations of CH improved water uptake, but the inclusion of a high concentration of  
350 plasticizer (40%), generated the opposite effect. A similar analysis was done observing  
351 Figure 1E, samples S3 and S1. Mucoadhesive strength results showed no significant  
352 differences among the formulated films ( $p > 0.01$ ). Several works reported that as the  
353 swelling index increases the adhesive strength decreases. This fact is attributed to  
354 overhydration of the polymers that led to disentanglement at the polymers/tissue  
355 interface, resulting in an abrupt drop in adhesive strength (Bassi and Kaur, 2015; Peh and  
356 Wong, 1999). Based on the obtained result, the swelling of S2, despite being the highest,  
357 is not enough to decrease the adhesiveness of this formulation in comparison with S1, S3  
358 and S4 ( $p > 0.01$ ).


359

### 360 3.3. Spectroscopy data

361 Figure 2 shows the infrared spectra obtained for TCZ, polymers, plasticizer, commercial  
362 ovule and films. The FTIR-ATR spectrum of TCZ (Figure 2Aa, Table 2) was in agreement  
363 with the reference of the standard TCZ (KBr discs) of BP 2010 (British Pharmacopeia  
364 Commission, 2010). The characteristic peaks corresponding to  $\nu(\text{C}=\text{N})$  of the imidazol group  
365  $1562.3 \text{ cm}^{-1}$ ,  $\delta(\text{C}-\text{H})$   $1464.0 \text{ cm}^{-1}$ ,  $\nu(\text{C}=\text{C})$   $1433.1 \text{ cm}^{-1}$ ,  $\nu(\text{C}-\text{N})$   $1278.8 \text{ cm}^{-1}$ ,  $\nu(\text{C}-\text{O}-\text{C})$   
366  $1118.7 \text{ cm}^{-1}$ ,  $\nu(\text{C}-\text{S})$   $733.0 \text{ cm}^{-1}$  and  $\nu(\text{C}-\text{Cl})$   $626.9 \text{ cm}^{-1}$  were identified (Bisht et al., 2015;  
367 Crisóstomo-Lucas et al., 2015).

368





369

370 **Figure 2. FTIR-ATR spectra. A) Components of films: a) TCZ, b) CH, c) HPMC d)**

371 **PEG 400, B) Films and ovule: e) S1, f) S2, g) S3 h) S4 and i) Ovule.**

372

373 The ATR-FTIR spectrum of CH (Figure 2Ab) showed a typical band between 3000-  
 374 3600 cm<sup>-1</sup>, concerned with -OH groups, which is broad due to overlapping with the stretching  
 375 band of -NH (Pawlak and Mucha, 2003). Other bands were also observed centered at: 2925  
 376 cm<sup>-1</sup> (stretching vibration of C-H bond); 1643cm<sup>-1</sup> (amide I); 1595 cm<sup>-1</sup> (NH<sub>2</sub> bending)  
 377 (Tejada et al., 2017b); 1418 cm<sup>-1</sup> (carboxyl -COOH) (Li et al., 2005); 1326 cm<sup>-1</sup> (Amide III)  
 378 (Kumar et al., 2017); 1150 cm<sup>-1</sup> (stretching of the C-O-C bridge); 1060 cm<sup>-1</sup> and 1020 cm<sup>-1</sup>  
 379 associated to the C-O stretching vibration (Espinosa-Andrews et al., 2010); and finally the  
 380 band at 892 cm<sup>-1</sup> assigned to the absorption peaks of  $\beta$ -(1,4) glycosidic unions in CH (Yue et  
 381 al., 2009).

382 The HPMC spectrum (Figure 2Ac) in the region 3600-3200  $\text{cm}^{-1}$  shows a band  
383 associated with the presence of hydroxyl groups while the band in the region 3000-2800  $\text{cm}^{-1}$   
384 represents the absorptions of C–H vibration modes from methyl group (Ding et al., 2015).  
385 The band arising from –OH bonds on the glucose molecule appears at 1313  $\text{cm}^{-1}$  and the  
386 peaks at 1373 and 1451  $\text{cm}^{-1}$  resulted from C–H bending and stretching modes from methyl  
387 groups (Wang et al., 2007). The most intense peak in the HPMC spectrum occurred at  
388 1050  $\text{cm}^{-1}$  (C–O) and represents out-of-phase vibrations associated with an alkyl substituted  
389 cyclic ring containing ether linkages (Akinosho et al., 2013). The peak centered at 944  $\text{cm}^{-1}$   
390 represents the in-phase vibrations from ether linkages and appeared as a weaker band attached  
391 to the band at 1050  $\text{cm}^{-1}$  (Coates, 2000).

392 The spectrum of plasticizer (Figure 2Ad) PEG 400 presented a very intensive band  
393 around 1100  $\text{cm}^{-1}$  usually assigned in alcohols to either the  $\nu(\text{C–O})$  stretching or the in-plane  
394 bending ( $\delta$ ) vibration of the C–O–H-group, and in ethers to the stretching  $\nu(\text{C–O–C})$   
395 vibration. The stretching  $\nu(\text{C–C})$  and deformational  $\delta(-\text{CH}_2-)$  modes are also active in this  
396 range (Rozenberg et al., 1998). The vibration band at 1300  $\text{cm}^{-1}$  (antisymmetric stretch)  
397 corresponds to the C–O–C ether stretch (Alcantar et al., 2000), while at 1348  $\text{cm}^{-1}$  the (C–O–  
398 H) deformational (in-plane) band appears (Rozenberg et al., 1998). The bands peaking at  
399 2960 and 2869  $\text{cm}^{-1}$  correspond to –CH<sub>2</sub> stretching vibrations (Alcantar et al., 2000).

400 The films (Figure 2Be-h) showed additional bands corresponding to lactic acid at 1727  
401  $\text{cm}^{-1}$  (C=O group); at 1220  $\text{cm}^{-1}$  (O–H and C–O both from the acid group) and at 1120  $\text{cm}^{-1}$   
402 (C–O alcohol group).

403 Several differences were observed when evaluating the IR spectra of the commercial  
404 form and films (Figure 2B). The ovule (Figure 2Bi) presented only 7 bands, 4 of them may  
405 correspond to TCZ (at 733  $\text{cm}^{-1}$ , present in the spectrum as a shoulder; at 1338.6  $\text{cm}^{-1}$ ; at  
406 1375.3  $\text{cm}^{-1}$  and at 1456.5  $\text{cm}^{-1}$ ). In addition, the spectrum showed two bands comprised

407 between 2840 and 2950  $\text{cm}^{-1}$  corresponding to C-H stretches of alkanes due to excipients of  
 408 the ovule. The corresponding bands and assignments of the films developed are described in  
 409 Table 2.

410

411 **Table 2.** FTIR-ATR spectroscopic data and assignment of the developed systems.

Wavenumber ( $\text{cm}^{-1}$ )	S1	S2	S3	S4	Assignment
627*		+			TCZ
688	+	+			TCZ
743	+	+		Low intensity	TCZ
787	+	+		+	TCZ
883			+	+	PEG
945					HPMC
1120	+*	+		+	Lactic Acid
1220		+		+	Lactic Acid
1270-1315			+	+	PEG
1247			+	+*	PEG
1287		+			TCZ
1348		+	+	+	PEG
1727	+	+	+	+	Lactic Acid

412 \* Signals corresponding to a shoulder


413

414 

### 3.4. Thermal analysis

415 DSC curves show that TCZ exhibited a single endothermic peak (Figure 3A) without  
 416 shoulders at 82.8  $^{\circ}\text{C}$ , with an onset temperature of 77.6  $^{\circ}\text{C}$  associated with the melting process  
 417 (Ribeiro et al., 2016). This result is in agreement with the value reported (82  $^{\circ}\text{C}$ ) in the  
 418 literature (British Pharmacopeia Commission, 2013). The calculated melting heat was 71.17 J/g  
 419 and no re-crystallization peak was observed in the corresponding cooling curve. The  
 420 thermogram of the commercial ovule (Figure 3B) shows an endothermic peak centered at 80.4  
 421  $^{\circ}\text{C}$ , corresponding to the melting point of TCZ, which is slightly shifted to the right, probably  
 422 due to some interactions with the excipients. Similar shifts were observed in previous works  
 423 that studied drug-excipient compatibility. It was reported that these minor changes in the

424 melting endothermic peak of drug could be due to the mixing of drug and excipient, which  
 425 lowers the purity of each component in the mixture and may not necessarily indicate potential  
 426 incompatibility (Abrantes et al., 2016; Charde et al., 2008; Verma and Garg, 2005). On the  
 427 other hand, no endothermic peak related with TCZ was observed in DSC analysis of the films  
 428 (Figure 3C-F). The absence of the endothermic peak of TCZ could suggest that the drug is in  
 429 amorphous state when loaded in the films (Rask et al., 2018; Senta-Loys et al., 2017).  
 430




431  
 432 **Figure 3.** DSC thermograms. A) TCZ B) Ovule and C-F) films (S1, S2, S3, S4 respectively).  
 433

434 Regarding TGA (Table 4) and DTGA analysis, the commercial ovule exhibited 2 stages  
 435 of degradation (Figure 4A), unlike TCZ whose degradation takes place in one stage (max  
 436 peak 297.8 °C Figure 4A). The greatest loss of mass (92.24%) in the decomposition of the

437 ovule took place between 30 and 360 °C, with two maximum peaks of decomposition at 304.8  
 438 (related to TCZ) and 321.3 °C (related to excipients).

439



440  
 441 **Figure 4.** TGA and DTGA curves. A-B) TCZ and Ovule C-D) CH, HPMC, B2, B1, PEG 400  
 442 E-F) films S1, S2, S3, S4 and TCZ.

443  
 444 Figures 4C and 4D show that both polymers (HPMC and CH) in solid state showed 2  
 445 main degradation peaks, the first thermal event occurs in the temperature range 30-100 °C and  
 446 is attributed to the evaporation of water (de Britto and Campana-Filho, 2004). The second one  
 447 occurs in the temperature range 200-400 °C, and it is attributed to the thermal degradation of  
 448 each polymer (345.9 °C for HPMC/ 289.6 °C for CH respectively) (de Britto and Campana-  
 449 Filho, 2004; Li et al., 1999).

450 Films B1 and B2 containing only the polymers showed some differences with respect to  
451 solid polymers (Figures 4C and 4D). In the case of B1, 4 peaks can be observed; the first at  
452 59.1 °C is due to free water; the second, centered at 191.9 °C could be associated with water  
453 retained by polar interactions (Lavorgna et al., 2010); the next one, centered at 311.6 °C,  
454 corresponds to the fusion of CH (de Britto and Campana-Filho, 2004) and the last one,  
455 centered at 349.1 °C, corresponds to the fusion of HPMC (Li et al., 1999). B2 exhibited 3  
456 peaks; one centered at 94.1 °C associated to water linked through hydrogen bonds; another  
457 one at 179.5 °C, which is related to water retained by polar interactions and finally the peak  
458 at 281.1 °C, which is associated to the degradation of the polymer (Cardenas and Miranda,  
459 2004).

460 The DTGA curve of the plasticizer exhibited three peaks (Figure 4 D); the first one  
461 centered at 81.2 °C, is related to water linked through hydrogen bonds whereas the other two  
462 peaks, at 326.1 °C and 362.7 °C, correspond to the pyrolysis of PEG groups (Sadeghpour et al.,  
463 2018; Zhang et al., 2013).

464 The decomposition stages of the films can be observed in Figure 4E and 4F (Table 3).  
465 Whereas 3 stages are displayed for films based on CH, 4 stages were observed for films based  
466 on both polymers. For films S1 and S3, the first 2 peaks (52.7 and 171.1 °C for S1 and 56.8  
467 and 176.4 °C for S3) have the same meaning as for B2, i.e. water volatilization; the third  
468 could be associated to simultaneous degradation of the drug and the CH (268.8 °C for S1 and  
469 289.2 °C for S3), and the fourth peak is attributed to HPLC (353.5 and 353.1 °C). S2 and S4  
470 films exhibit only the first 3 peaks (Figure 4F) because these films do not contain HPMC in  
471 their composition. On the other hand, a decrease in the remaining mass was registered when  
472 the plasticizer concentration increased (Ramesh and Arof, 2001), independent of the polymer  
473 composition.

474

475 Table 3. TGA data.

	Remnant mass (%)	Stage 1 (°C)	Peak (°C)	Stage 2 (°C)	Peak (°C)	Stage 3 (°C)	Peak (°C)	Stage 4 (°C)	Peak (°C)
<b>TCZ</b>		180-307	297.8						
<b>Ovule</b>	-	30-360	304.8/321.3	360-550					
<b>S1</b>	9,98	25-100	52.70	100-215	171.02	215-304	268.78	304-425	353.54
<b>S2</b>	25,95	25-133	90.31	133-234	186.31	234-478	281.25		
<b>S3</b>	8,62	25-105	56.80	100-224	176.45	224-310	289.20	310-433	353.03
<b>S4</b>	16,06	25-123	81.57	123-240	185.95	240-478	292.39		


476

## 477 3.5. XRD analysis

478 The crystalline character of the drug was analyzed through an XRD analysis (Figure 5).  
479 The TCZ raw material (Figure 5A) showed an intense peak at 22.33 °, which was mentioned  
480 in a previous report (Ribeiro et al., 2016). Also, diffraction peaks at 2 $\theta$  around 8.71 °; 10.39 °;  
481 13.49 °; 13.67 °; 13.83 °; 16.35 °; 17.45 °; 17.93 °; 18.71 °; 20.33 °; 20.69 °; 24.01 °; 24.61 °;  
482 25.33 °; 25.67 °; 26.27 °; 27.31 °; 27.53 °; 28.39 °; 28.99 °; 29.39 °; 29.83 °; 31.47 °; 32.17 °;  
483 32.77 °; 33.13 ° 36.95 ° and 38.59 ° were observed. The ovule (Figure 5B) showed 8 peaks  
484 corresponding to the TCZ at 22.33 °, 27.31 °, 27.53 °, 28.39 °, 29.83 °, 31.47 °, 32.17 ° and  
485 33.13 °. Probably, the reduction in the intensities of the peaks regarding TCZ raw material is  
486 due to the excipient dilution effect. On the other hand, no peaks were observed when  
487 analyzing the spectra of the films (Figure 5 C-F), which is in agreement with the results  
488 obtained by DSC, confirming the hypothesis that TCZ is in amorphous state inside the films  
489 (Yang et al., 2018).

490





491

492 **Figure 5.** XRD pattern. A) TCZ B) Ovule C) S1 D) S2 E) S3 F) S4

493


## 494 3.6. SEM analysis

495 Morphology of films was analyzed by SEM (Figure 6). Figure 6A-D shows the SEM  
 496 images of the surface and cross-sectional fracture of the films studied. The morphology of the  
 497 films shows that all formulations were symmetric and uniformly distributed. In superficial  
 498 section, film S1 based on CH-HPMC with 5% w/w PEG 400 (Figure 6A-A<sub>2</sub>) presented a  
 499 homogeneous and smooth surface even at 5000x magnification, while film S3 based on CH-  
 500 HPMC with 40% w/w PEG 400 presented a few signs of roughness at 5000x (Figure 6C<sub>2</sub>)  
 501 which may be attributed to the increase in the plasticizer content. On the other hand, films  
 502 based only on CH (S2 and S4) showed to be porous and presented roughness at higher  
 503 magnifications (Figure 6B<sub>3</sub> and D<sub>3</sub>), which could be related to the interaction between CH and



504 the plasticizer during the drying process (Al-Hassan and Norziah, 2012). As observed, the  
 505 roughness increased in films containing 40% w/w PEG 400 (Figure 6C<sub>2</sub> and D<sub>2</sub>).

506



507

508 **Figure 6.** Scanning electron microscopy. A) S1 B) S2 (C) S3 (D) S4. Micrographs with  
 509 different magnifications and orientation. Surface: A.D) 200x A<sub>1</sub>.D<sub>1</sub>) 1000x A<sub>2</sub>.D<sub>2</sub>) 5000x and  
 510 film transversal section B<sub>3</sub>.D<sub>3</sub>)1000x.

511

512 It is important to remark that films based on CH and HPMC (Figure 6A and 6C)  
 513 presented a dense and compact structure, suggesting high structural integrity and good  
 514 compatibility between the components (Villacrés et al., 2014).


515

516

## 517 3.7. Dissolution Studies

518 Figure 7 shows the dissolution profiles of TCZ raw material and films. The films  
 519 showed fast drug release, reaching almost 100% after 60 min (Figure 7). At 30 min assay,  
 520 only 3.9 % of TCZ raw material was released ( $Q_{30}=3.9\%$ ), while the films allowed a  
 521 significant improvement in TCZ dissolution rate (S1  $Q_{30}=96.0\%$ , S2  $Q_{30}=88.2\%$ , S3  $Q_{30}=  
 522 97.5\%$ , and S4  $Q_{30}=83.5\%$ ). The result is probably due to the fact that TZC modified its solid  
 523 state when loaded in the films, as observed in DSC and XRD analysis. On the other hand,  
 524 TCZ raw material presented incomplete dissolution after 360 min assay ( $Q_{360}=14.6\%$ ). This  
 525 poor dissolution is related to the TCZ structure, which is highly hydrophobic, belonging in  
 526 class II in the Biopharmaceutical classification system (BCS) (Kasim et al., 2004).

527 This assay is useful for the analysis of TCZ release from the films; however, the assay  
 528 conditions are not representative of the vaginal cavity, which presents humidity instead of 900  
 529 mL of fluid. To study TCZ release as well as its activity over time in a humid medium, the  
 530 “halo zone test over time” was carried out.



531  
 532 **Figure 7.** Dissolution profiles of TCZ and the films loaded with TCZ.


533

## 534 3.8. Biological activity

## 535 3.8.1. Halo zone test over time

536 Halo zone test over time was performed in order to analyze both the release of TCZ and  
537 the activity of different formulations over time when exposed to a humid zone. Figure 8  
538 shows the different halos produced over time by TZC raw material (added to a Scotch tape  
539 disc), ovule content (embedded in a disc of absorbent paper), different film formulations, and  
540 empty films (B1 and B2). As observed B2 based on 100% CH showed activity for 48 h, while  
541 no inhibition halo was observed when B1 (based on CH:HPMC) was assayed. The ovule  
542 presented antifungal activity until the end of the assay (5 mm). Films loaded with TZC  
543 showed greater activity than both the ovule and TCZ raw material, producing inhibition halos  
544 between 26-34 mm of diameters after 96 h assay. After 96 h, the percentage of reduction in  
545 the diameter of the halo for the ovule in comparison with the first determination (2 h) was  
546 89%, while the films showed reductions between 24 and 41% (S1= 35 % S2= 24 % S3= 38 %  
547 S4= 41 %), suggesting a more time-sustained release of TCZ for the films.

548 No differences were observed between the behavior of the S3 and S4 formulations at the  
549 end of the assay. On the other hand, S2 film (based on 100% CH and 5% PEG 400) produced  
550 the highest inhibition halo at 24, 48, 72, and 96 h ( $p < 0.01$ ); this result could be related with  
551 both the swelling (Figure 1E) of the formulation (related with the highest release of TCZ from  
552 the matrix to the culture medium) (Shu et al., 2001) and the activity of CH (observed in B2).



553


554 **Figure 8.** Halo zone produced by TCZ, films (S1-S4 and B2) and the commercial ovule.

555

## 556 3.8.2. Time-kill

557 Time-kill studies were performed to assess the exposure time required to kill a  
 558 standardized *Candida* inoculum. Plots of TCZ activity were built as CFU/mL versus time  
 559 (Figure 9). Times to obtain 99.9% reduction in the number of CFU/mL were different for each  
 560 formulation. It was observed that the control curve did not show any decrease in the number  
 561 of colony forming units compared with the initial inoculums, while a reduction in CFU was  
 562 observed even when unloaded film only containing CH was assayed. It has been reported that  
 563 low concentrations of CH produce a series of alterations of ion homeostasis and metabolism  
 564 of the yeast while at high concentrations it may act as a permeation agent for bacteria and  
 565 fungi (Peña et al., 2013). Thus, when CH is used at concentrations higher than 1.0 mg/mL, not  
 566 only a fungistatic but also a fungicidal activity is observed. In this assay the CH concentration

567 (when placing unloaded film based only on CH into the medium) was higher than 1.0 mg/mL,  
 568 therefore, this unloaded film (B2) presented fungicidal activity itself. On the other hand, when  
 569 CH was used at 25% (B1) the concentration in the medium was lower than 1.0 mg/mL and no  
 570 decrease in the number of colony forming units compared with the initial inoculums was  
 571 observed.



572

573 **Figure 9.** CFU/mL surviving at each time point in the presence and absence of the different  
 574 formulations.

575

576 When TCZ was loaded, the activity of the formulations was directly related to the drug,  
 577 and just small differences between time-kill curves of loaded films (S1-S4) were found  
 578 (Figure 9). The fastest activity was obtained when loaded CH (15 minutes) or CH-HPMC (30  
 579 minutes) based films were assayed; on the other hand, both TCZ raw material and the ovule  
 580 needed 360 minutes to reach this reduction. This was probably related to the higher and faster  
 581 dissolution of TCZ when it is loaded in the films (Figure 7), which may improve its diffusion


582 in the agar medium. This increase in TCZ diffusion may explain the higher activity of the  
 583 films with respect to TCZ pure drug and ovule.

584

### 585 3.9. Cytotoxicity of loaded and unloaded films

586 Regarding cytotoxicity (Figure 10), films only based on CH induced a 35 to 54 % reduction in  
 587 cell viability after 24 h incubation, as compared to control films. It has been reported that CH  
 588 seems to be cytostatic towards fibroblasts; due to the fact that it inhibits cell proliferation.  
 589 Thus, CH-based materials would alter cell growth; however, Shahabeddin et. al found that  
 590 combinations of CH with other materials, such as collagen and glycosaminoglycans, allow  
 591 improvement of its cytocompatibility (Shahabeddin et al., 1991). On the other hand, films  
 592 based on CH-HPMC (loaded and unloaded) did not produce any cytotoxicity effects.

593



594

595 Figure 10. Cytotoxicity of loaded and unloaded films

596



### 597 3. Conclusions

598 In this work, vaginal films based on CH alone and combined with HPMC using different  
599 contents of PEG as plasticizer were successfully developed and characterized as an alternative  
600 dosage form for the treatment of vaginal candidiasis. Formulated films showed similar  
601 mechanical properties and adhesiveness. The films were able to swell for 24 h without  
602 suffering disintegration; however, films based only on CH showed the highest swelling and,  
603 therefore, may produce discomfort after application. The developed films displayed faster  
604 activity against *Candida albicans* than both TCZ pure drug and TCZ ovule, which is probably  
605 associated with the fact that TCZ is inside the films in amorphous state. Additionally, films  
606 presented controlled release of TCZ, showing strong antifungal activity after 96 h assay.  
607 Those formulations based only on CH presented a certain degree of cytotoxicity and,  
608 therefore, their use should be avoided. The system based on CH-HPMC with 40% PEG 400  
609 as plasticizer showed fast and sustained antimicrobial activity and also the lowest swelling  
610 value. Additionally, this formulation produced no cytotoxic effects, showing that this film is a  
611 promising alternative dosage form for the treatment of vaginal candidiasis. All these tests  
612 should be supplemented by *in vivo* tests in the near future.

613

### 614 Acknowledgements

615 The authors gratefully acknowledge Consejo Nacional de Investigaciones Científicas y  
616 Técnicas (CONICET), Agencia Nacional de Promoción de Ciencia y Tecnología (ANPCyT),  
617 and Universidad Nacional de Rosario (UNR) for their financial support. NLC is also thankful  
618 to CONICET for her fellowship. ADQ thanks Carla G. Comanzo for technical assistance in  
619 cytotoxicity assays. In addition, we would like to thank the staff from the English Department  
620 (Facultad de Cs. Bioquímicas y Farmacéuticas, Universidad Nacional de Rosario) for the  
621 language correction of the manuscript.

622

**Figure Captions**

623 **Figure 1.** A) Thickness, B) Elongation at break C) Load at break D) Mucoadhesive strength  
624 E) Swelling index

625 **Figure 2.** FTIR-ATR spectra. A) Components of films: a) TCZ, b) CH, c) HPMC d) PEG  
626 400, B) Films and ovule: e) S1, f) S2, g) S3 h) S4 and i) Ovule

627 **Figure 3.** DSC thermograms. A) TCZ B) Ovule and C-F) films (S1, S2, S3, S4 respectively)

628 **Figure 4.** TGA and DTGA curves. A-B) TCZ and Ovule C-D) CH, HPMC, B2, B1, PEG 400  
629 E-F) films S1, S2,S3,S4 and TCZ.

630 **Figure 5.** XRD pattern. A) TCZ B) Ovule C) S1 D) S2 E) S3 F) S4

631 **Figure 6.** Scanning electron microscopy. A) TCZ. B) S1 C) S2 (D) S3 (E) S4. Micrographs  
632 with different magnifications and orientation. Surface: A.F) 200x A<sub>1</sub>-F<sub>1</sub>) 1000x A<sub>2</sub>-F<sub>2</sub>) 5000x  
633 and film transversal section B<sub>3</sub>-F<sub>3</sub>)1000x

634 **Figure 7.** Dissolution profiles of TCZ and the films loaded with TCZ.

635 **Figure 8.** Inhibition halos produced by TCZ, films (S1-S4 and B2) and the commercial ovule.

636 **Figure 9.** CFU/mL surviving at each time point in the presence and absence of the different  
637 formulations.

638 **Figure 10.** Cytotoxicity of loaded and unloaded films

639

**References**

- 641 Abrantes, C.G., Duarte, D., Reis, C.P., 2016. An Overview of Pharmaceutical Excipients: Safe or Not  
642 Safe? *Journal of Pharmaceutical Sciences* 105, 2019-2026.
- 643 Akinosho, H., Hawkins, S., Wicker, L., 2013. Hydroxypropyl methylcellulose substituent analysis and  
644 rheological properties. *Carbohydrate polymers* 98, 276-281.
- 645 Al-Hassan, A.A., Norziah, M.H., 2012. Starch–gelatin edible films: Water vapor permeability and  
646 mechanical properties as affected by plasticizers. *Food Hydrocolloids* 26, 108-117.
- 647 Alam, M.A., Ahmad, F.J., Khan, Z.I., Khar, R.K., Ali, M., 2007. Development and evaluation of acid-  
648 buffering bioadhesive vaginal tablet for mixed vaginal infections. *AAPS PharmSciTech* 8, 229.
- 649 Alcantar, N.A., Aydil, E.S., Israelachvili, J.N., 2000. Polyethylene glycol-coated biocompatible surfaces.  
650 *Journal of biomedical materials research* 51, 343-351.
- 651 Allen, D.D., Caviedes, R., Cárdenas, A.M., Shimahara, T., Segura-Aguilar, J., Caviedes, P.A., 2005. Cell  
652 Lines as In Vitro Models for Drug Screening and Toxicity Studies. *Drug Development and Industrial*  
653 *Pharmacy* 31, 757-768.




- 654 Avachat, A.M., Gujar, K.N., Wagh, K.V., 2013. Development and evaluation of tamarind seed  
655 xyloglucan-based mucoadhesive buccal films of rizatriptan benzoate. *Carbohydrate polymers* 91,  
656 537-542.
- 657 Bassi, P., Kaur, G., 2015. Bioadhesive vaginal drug delivery of nystatin using a derivatized polymer:  
658 development and characterization. *European Journal of Pharmaceutics and Biopharmaceutics* 96,  
659 173-184.
- 660 Beggs, W.H., 1984. Fungicidal activity of tioconazole in relation to growth phase of *Candida albicans*  
661 and *Candida parapsilosis*. *Antimicrobial agents and chemotherapy* 26, 699-701.
- 662 Bisht, D.S., Bhatt, G.K., Kothiyal, P., 2015. Formulation and Evaluation of Nail Lacquer Containing  
663 Tioconazole for Transungual Drug Delivery System. *Indo Am. J. Pharm. Sci.* 2, 1474-1485.
- 664 British Pharmacopeia Commission, 2013. Tioconazole impurity standard.
- 665 British Pharmacopeia Commission, 2010. *British Pharmacopeia*, Londres.
- 666 Cantón, E., Pemán, J., Valentín, A., Espinel-Ingroff, A., Gobernado, M., 2009. In vitro activities of  
667 echinocandins against *Candida krusei* determined by three methods: MIC and minimal fungicidal  
668 concentration measurements and time-kill studies. *Antimicrobial agents and chemotherapy* 53,  
669 3108-3111.
- 670 Cardenas, G., Miranda, S.P., 2004. FTIR and TGA studies of chitosan composite films. *Journal of the*  
671 *Chilean Chemical Society* 49, 291-295.
- 672 Carrillo-Muñoz, A.J., Tur-Tur, C., Hernández-Molina, J.M., Santos, P., Cárdenes, D., Giusiano, G., 2010.  
673 Antifúngicos disponibles para el tratamiento de las micosis ungueales. *Revista iberoamericana de*  
674 *micología* 27, 49-56.
- 675 Cautela, M.P., Moshe, H., Sosnik, A., Sarmento, B., das Neves, J., 2018. Composite films for vaginal  
676 delivery of tenofovir disoproxil fumarate and emtricitabine. *European Journal of Pharmaceutics and*  
677 *Biopharmaceutics*.
- 678 Coates, J., 2000. Interpretation of infrared spectra, a practical approach. *Encyclopedia of analytical*  
679 *chemistry*.
- 680 Conzatti, G., Chamary, S., De Geyter, N., Cavalie, S., Morent, R., Tournette, A., 2018. Surface  
681 functionalization of plasticized chitosan films through PNIPAM grafting via UV and plasma graft  
682 polymerization. *European Polymer Journal*.
- 683 Costa-de-Oliveira, S., Pina-Vaz, C., Mendonca, D., Rodrigues, A.G., 2008. A first Portuguese  
684 epidemiological survey of fungaemia in a university hospital. *European Journal of Clinical*  
685 *Microbiology & Infectious Diseases* 27, 365-374.
- 686 Crisóstomo-Lucas, C., García-Holley, P., Hernández-Ortega, S., Sánchez-Bartéz, F., Gracia-Mora, I.,  
687 Barba-Behrens, N., 2015. Structural characterization and cytotoxic activity of tioconazole  
688 coordination compounds with cobalt(II), copper(II), zinc(II) and cadmium(II). *Inorganica Chimica Acta*  
689 438, 245-254.
- 690 Charde, S., Mudgal, M., Kumar, L., Saha, R., 2008. Development and evaluation of buccoadhesive  
691 controlled release tablets of lercanidipine. *AAPS PharmSciTech* 9, 182-190.
- 692 de Britto, D., Campana-Filho, S.P., 2004. A kinetic study on the thermal degradation of N,N,N-  
693 trimethylchitosan. *Polymer Degradation and Stability* 84, 353-361.
- 694 Dey, A., Kamat, A., Nayak, S., Danino, D., Kesselman, E., Dandekar, P., Jain, R., 2018. Role of proton  
695 balance in formation of self-assembled chitosan nanoparticles. *Colloids and Surfaces B: Biointerfaces*  
696 166, 127-134.
- 697 Ding, C., Zhang, M., Li, G., 2015. Preparation and characterization of collagen/hydroxypropyl  
698 methylcellulose (HPMC) blend film. *Carbohydrate Polymers* 119, 194-201.
- 699 Dobarra, N.B., Badhan, A., Mashru, R., 2009. A novel itraconazole bioadhesive film for vaginal  
700 delivery: design, optimization, and physicochemical characterization. *Aaps Pharmscitech* 10, 951.
- 701 Domjan, A., Bajdik, J., Pintye-Hodi, K., 2009. Understanding of the plasticizing effects of glycerol and  
702 PEG 400 on chitosan films using solid-state NMR spectroscopy. *Macromolecules* 42, 4667-4673.
- 703 Egan, M.E., Lipsky, M.S., 2000. Diagnosis of vaginitis. *American family physician* 62, 1095-1104.

- 704 Espinosa-Andrews, H., Sandoval-Castilla, O., Vázquez-Torres, H., Vernon-Carter, E.J., Lobato-Calleros,  
705 C., 2010. Determination of the gum Arabic–chitosan interactions by Fourier Transform Infrared  
706 Spectroscopy and characterization of the microstructure and rheological features of their  
707 coacervates. *Carbohydrate Polymers* 79, 541-546.
- 708 Ferretti, A.C., Tonucci, F.M., Hidalgo, F., Almada, E., Larocca, M.C., Favre, C., 2016. AMPK and PKA  
709 interaction in the regulation of survival of liver cancer cells subjected to glucose starvation.  
710 *Oncotarget* 7, 17815-17828.
- 711 Ghosal, K., Ranjan, A., Bhowmik, B.B., 2014. A novel vaginal drug delivery system: anti-HIV  
712 bioadhesive film containing abacavir. *Journal of Materials Science: Materials in Medicine* 25, 1679-  
713 1689.
- 714 Kamel, S., Ali, N., Jahangir, K., Shah, S., El-Gendy, A., 2008. Pharmaceutical significance of cellulose: a  
715 review. *Express Polym Lett* 2, 758-778.
- 716 Kasim, N.A., Whitehouse, M., Ramachandran, C., Bermejo, M., Lennernäs, H., Hussain, A.S.,  
717 Junginger, H.E., Stavchansky, S.A., Midha, K.K., Shah, V.P., Amidon, G.L., 2004. Molecular Properties  
718 of WHO Essential Drugs and Provisional Biopharmaceutical Classification. *Molecular Pharmaceutics* 1,  
719 85-96.
- 720 Krajewska, B., 2004. Application of chitin-and chitosan-based materials for enzyme immobilizations: a  
721 review. *Enzyme and microbial technology* 35, 126-139.
- 722 Kumar, N., Devineni, S.R., Gajjala, P.R., Dubey, S.K., Kumar, P., 2017. Synthesis, isolation,  
723 identification and characterization of new process-related impurity in isoproterenol hydrochloride by  
724 HPLC, LC/ESI-MS and NMR. *J. Pharm. Anal.* 7, 394-400.
- 725 Lavorgna, M., Piscitelli, F., Mangiacapra, P., Buonocore, G.G., 2010. Study of the combined effect of  
726 both clay and glycerol plasticizer on the properties of chitosan films. *Carbohydrate Polymers* 82, 291-  
727 298.
- 728 Lefler, E., Stevens, D.A., 1984. Inhibition and killing of *Candida albicans* in vitro by five imidazoles in  
729 clinical use. *Antimicrobial agents and chemotherapy* 25, 450-454.
- 730 Li, X.-G., Huang, M.-R., Bai, H., 1999. Thermal decomposition of cellulose ethers. *Journal of Applied*  
731 *Polymer Science* 73, 2927-2936.
- 732 Li, Z., Ramay, H.R., Hauch, K.D., Xiao, D., Zhang, M., 2005. Chitosan–alginate hybrid scaffolds for bone  
733 tissue engineering. *Biomaterials* 26, 3919-3928.
- 734 Machado, A., Cunha-Reis, C., Araújo, F., Nunes, R., Seabra, V., Ferreira, D., das Neves, J., Sarmento,  
735 B., 2016. Development and in vivo safety assessment of tenofovir-loaded nanoparticles-in-film as a  
736 novel vaginal microbicide delivery system. *Acta biomaterialia* 44, 332-340.
- 737 Mishra, R., Soni, K., Mehta, T., 2017. Mucoadhesive vaginal film of fluconazole using cross-linked  
738 chitosan and pectin. *Journal of Thermal Analysis and Calorimetry* 130, 1683-1695.
- 739 Owen, D.H., Katz, D.F., 1999. A vaginal fluid simulant. *Contraception* 59, 91-95.
- 740 Pawlak, A., Mucha, M., 2003. Thermogravimetric and FTIR studies of chitosan blends. *Thermochemica*  
741 *acta* 396, 153-166.
- 742 Peh, K.K., Wong, C.F., 1999. Polymeric films as vehicle for buccal delivery: swelling, mechanical, and  
743 bioadhesive properties. *J Pharm Pharm Sci* 2, 53-61.
- 744 Peña, A., Sánchez, N.S., Calahorra, M., 2013. Effects of chitosan on *Candida albicans*: conditions for  
745 its antifungal activity. *BioMed research international* 2013.
- 746 Pharmacopoeia, U., 2017. USP 40, NF 35, Pharmacopoeia, US -National Formulary. Rockville: USP 2.
- 747 Priotti, J., Codina, A.V., Leonardi, D., Vasconi, M.D., Hinrichsen, L.I., Lamas, M.C., 2017. Albendazole  
748 microcrystal formulations based on chitosan and cellulose derivatives: physicochemical  
749 characterization and in vitro parasitocidal activity in *Trichinella spiralis* adult worms. *AAPS*  
750 *PharmSciTech* 18, 947-956.
- 751 Ramesh, S., Arof, A.K., 2001. Structural, thermal and electrochemical cell characteristics of poly(vinyl  
752 chloride)-based polymer electrolytes. *Journal of Power Sources* 99, 41-47.
- 753 Rask, M.B., Knopp, M.M., Olesen, N.E., Holm, R., Rades, T., 2018. Comparison of two DSC-based  
754 methods to predict drug-polymer solubility. *International Journal of Pharmaceutics* 540, 98-105.


- 755 Ribeiro, R.F., Motta, M.H., Härter, A.P.G., Flores, F.C., Beck, R.C.R., Schaffazick, S.R., da Silva, C.d.B.,  
756 2016. Spray-dried powders improve the controlled release of antifungal tioconazole-loaded  
757 polymeric nanocapsules compared to with lyophilized products. *Materials Science and Engineering: C*  
758 59, 875-884.
- 759 Rozenberg, M., Loewenschuss, A., Marcus, Y., 1998. IR spectra and hydration of short-chain  
760 polyethyleneglycols. *Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy* 54, 1819-  
761 1826.
- 762 Sadeghpour, M., Yusoff, R., Aroua, M.K., Tabandeh, M., 2018. Modification of polyethylene glycol  
763 with choline chloride and evaluation of the CO<sub>2</sub> absorption capacity of their aqueous solutions.  
764 *Greenhouse Gases: Science and Technology* 8, 324-334.
- 765 Saha, D., Bhattacharya, S., 2010. Hydrocolloids as thickening and gelling agents in food: a critical  
766 review. *Journal of food science and technology* 47, 587-597.
- 767 Senta-Loys, Z., Bourgeois, S., Valour, J.-P., Briançon, S., Fessi, H., 2017. Orodispersible films based on  
768 amorphous solid dispersions of tetrabenazine. *International Journal of Pharmaceutics* 518, 242-252.
- 769 Shahabeddin, L., Damour, O., Berthod, F., Rousselle, P., Saintigny, G., Collombel, C., 1991.  
770 Reconstructed skin from co-cultured human keratinocytes and fibroblasts on a chitosane cross-linked  
771 collagen-GAG matrix. *Journal of Materials Science: Materials in Medicine* 2, 222-226.
- 772 Shaker, D.S., Ismail, S., Hamed, S., El-Shishtawy, E.M., 2018. Butoconazole nitrate vaginal sponge:  
773 Drug release and antifungal efficacy. *Journal of Drug Delivery Science and Technology* 48, 274-287.
- 774 Shu, X., Zhu, K., Song, W., 2001. Novel pH-sensitive citrate cross-linked chitosan film for drug  
775 controlled release. *International journal of pharmaceutics* 212, 19-28.
- 776 Srinivasan, P., Zhang, J., Martin, A., Kelley, K., McNicholl, J.M., Buckheit, R.W., Smith, J.M., Ham, A.S.,  
777 2016. Safety and pharmacokinetics of quick-dissolving polymeric vaginal films delivering the  
778 antiretroviral IQP-0528 for preexposure prophylaxis. *Antimicrobial agents and chemotherapy* 60,  
779 4140-4150.
- 780 Suyatma, N.E., Tighzert, L., Copinet, A., Coma, V., 2005. Effects of hydrophilic plasticizers on  
781 mechanical, thermal, and surface properties of chitosan films. *Journal of Agricultural and Food*  
782 *Chemistry* 53, 3950-3957.
- 783 Tejada, G., Barrera, M., Piccirilli, G., Sortino, M., Frattini, A., Salomón, C., Lamas, M.C., Leonardi, D.,  
784 2017a. Development and evaluation of buccal films based on chitosan for the potential treatment of  
785 oral candidiasis. *AAPS PharmSciTech* 18, 936-946.
- 786 Tejada, G., Lamas, M., Sortino, M., Alvarez, V., Leonardi, D., 2018a. Composite Microparticles Based  
787 on Natural Mucoadhesive Polymers with Promising Structural Properties to Protect and Improve the  
788 Antifungal Activity of Miconazole Nitrate. *AAPS PharmSciTech*, 1-11.
- 789 Tejada, G., Lamas, M.C., Svetaz, L., Salomón, C.J., Alvarez, V.A., Leonardi, D., 2018b. Effect of drug  
790 incorporation technique and polymer combination on the performance of biopolymeric antifungal  
791 buccal films. *International Journal of Pharmaceutics* 548, 431-442.
- 792 Tejada, G., Piccirilli, G., Sortino, M., Salomón, C., Lamas, M., Leonardi, D., 2017b. Formulation and in-  
793 vitro efficacy of antifungal mucoadhesive polymeric matrices for the delivery of miconazole nitrate.  
794 *Materials Science and Engineering: C* 79, 140-150.
- 795 Traore, Y.L., Fumakia, M., Gu, J., Ho, E.A., 2018. Dynamic mechanical behaviour of nanoparticle  
796 loaded biodegradable PVA films for vaginal drug delivery. *Journal of biomaterials applications* 32,  
797 1119-1126.
- 798 Verma, R.K., Garg, S., 2005. Selection of excipients for extended release formulations of glipizide  
799 through drug–excipient compatibility testing. *Journal of pharmaceutical and biomedical analysis* 38,  
800 633-644.
- 801 Vieira, M.G.A., da Silva, M.A., dos Santos, L.O., Beppu, M.M., 2011. Natural-based plasticizers and  
802 biopolymer films: A review. *European Polymer Journal* 47, 254-263.
- 803 Villacrés, R.A.E., Flores, S.K., Gerschenson, L.N., 2014. Biopolymeric antimicrobial films: study of the  
804 influence of hydroxypropyl methylcellulose, tapioca starch and glycerol contents on physical  
805 properties. *Materials Science and Engineering: C* 36, 108-117.

806 Wang, L., Dong, W., Xu, Y., 2007. Synthesis and characterization of hydroxypropyl methylcellulose  
 807 and ethyl acrylate graft copolymers. *Carbohydrate Polymers* 68, 626-636.  
 808 Wang, Q.Z., Chen, X.G., Liu, N., Wang, S.X., Liu, C.S., Meng, X.H., Liu, C.G., 2006. Protonation  
 809 constants of chitosan with different molecular weight and degree of deacetylation. *Carbohydrate*  
 810 *Polymers* 65, 194-201.  
 811 Yang, J., Alvebratt, C., Lu, X., Bergström, C.A.S., Strømme, M., Welch, K., 2018. Amorphous  
 812 magnesium carbonate nanoparticles with strong stabilizing capability for amorphous ibuprofen.  
 813 *International Journal of Pharmaceutics* 548, 515-521.  
 814 Yoo, J.-W., Acharya, G., Lee, C.H., 2009. In vivo evaluation of vaginal films for mucosal delivery of  
 815 nitric oxide. *Biomaterials* 30, 3978-3985.  
 816 Yue, W., He, R., Yao, P., Wei, Y., 2009. Ultraviolet radiation-induced accelerated degradation of  
 817 chitosan by ozone treatment. *Carbohydrate Polymers* 77, 639-642.  
 818 Zhang, L., Wang, Z., Lu, Z., Shen, H., Huang, J., Zhao, Q., Liu, M., He, N., Zhang, Z., 2013. PEGylated  
 819 reduced graphene oxide as a superior ssRNA delivery system. *Journal of Materials Chemistry B* 1,  
 820 749-755.  
 821


## Vaginal films




## Mechanical properties



## Biological Activity



## Cytotoxicity



822